logo
Sign in

EUPRAXIA PHARMACEUTICALS INC.

VICTORIA, A1 · Founded 2012 · Biotech · Public

extended-release drug delivery system for targeted therapeutics

Claim this profile

Follows are private to you and power your alerts

Updated · eupraxiapharma.com

Sector
Biotech
Headquarters
VICTORIA, A1
Founded
2012
Latest Form D
$1.9M, Nov 2024
Total capital
$2.5M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$2.5M
8 Form D · last Nov 2024
24 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
2
18 pending · first 2022
Rank in peer group#397 of 1449

Capital timeline

201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $2.5M3rd Form D$377K6th Form D$38K7th Form D$128K
201320152017201920212023FEDERAL ↑EQUITY ↓Cumulative $2.5M7th Form D$128K

Latest events

  • Private capital raisedForm D · SEC · 8th filing$1.9M
  • Private capital raisedForm D · SEC · 7th filing$128K
  • Private capital raisedForm D · SEC · 6th filing$38K
  • Private capital raisedForm D · SEC · 5th filing$24K
  • Private capital raisedForm D · SEC · 4th filing$5K
  • Private capital raisedForm D · SEC · 3rd filing$377K
  • Private capital raisedForm D · SEC · 2nd filing$24K
  • Private capital raisedForm D · SEC · 1st filing$10K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#397 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • JAMES HELLIWELLResearcherExecutive Officer, DirectorLinked by 2 patents
  • Amanda MaloneExecutive OfficerNamed in SEC Form D filings
  • Bruce A CousinsExecutive OfficerNamed in SEC Form D filings
  • DAVID STADNYKDirectorNamed in SEC Form D filings
  • GEORGE TSAFALASExecutive OfficerNamed in SEC Form D filings
  • JOHN MONTALBANODirectorNamed in SEC Form D filings
Show all 14 people
  • Joseph FreedmanDirectorNamed in SEC Form D filings
  • Mark A KowalskiExecutive OfficerNamed in SEC Form D filings
  • Michael WilminkDirectorNamed in SEC Form D filings
  • Paul A BrennanExecutive OfficerNamed in SEC Form D filings
  • Paul GeyerDirectorNamed in SEC Form D filings
  • Rahul SarugaserExecutive OfficerNamed in SEC Form D filings
  • Richard GlickmanDirectorNamed in SEC Form D filings
  • SIMON PIMSTONEDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 20
Show all 20 patent records
  • Sustained Release Of Formulations Of Local AnestheticsDec 2, 2025 · US 12,485,097Granted
  • Long-acting Intra-articular Dosage Forms Containing Fluticasone Propionate And Use ThereofDec 26, 2024 · Application 18753995Pending
  • Sustained Release Of Formulations Of Local AnestheticsJun 7, 2022 · US 11,351,124Granted
  • Process For Making Drug Crystals Of Desired Size Distribution And MorphologyJun 2, 2022 · Application 17594208Pending
  • Sustained Local Delivery Of Drugs Including AntibioticsFeb 22, 2018 · Application 15679546Pending
  • Injectable Microparticles For Hyper-localized Release Of Therapeutic AgentsAug 31, 2017 · Application 15511422Pending
  • Process For Making Drug Crystals Of Desired Size Distribution And MorphologyApplication 62832179Pending
  • Sustained Local Delivery Of Drugs Including AntibioticsApplication PCTUS2017047410Pending
  • Sustained Release Formulations Of Local AnestheticsApplication PCTUS2016059141Pending
  • Sustained Local Delivery Of Drugs Including AntibioticsApplication 62376204Pending
  • Sustained Release Formulations Of Local AnestheticsApplication 62247159Pending
  • Injectable Microparticles For Hyper-localized Release Of Therapeutic AgentsApplication PCTUS2015051072Pending
  • Injectable Microparticles For Hyper-localized Release Of Therapeutic AgentsApplication 62052959Pending
  • Double Barrel Syringe And Method To Use Same For Placement Confirmation And Joint Space InjectionApplication 61893771Pending
  • Use Of Long-acting Fluticasone Propionate Injectable Suspensions For Treating And Preventing Inflammations Of The Gastrointestinal TractApplication 19118306Pending
  • Long-acting Intra-articular Dosage Forms Containing Fluticasone Propionate And Use ThereofApplication PCTUS2024035464Pending
  • Use Of Long-acting Fluticasone Propionate Injectable Suspensions For Treating And Preventing Inflammations Of The Gastrointestinal TractApplication PCTUS2023075874Pending
  • Long-acting Intra-articular Dosage Forms Containing Fluticasone Propionate And Use ThereofApplication 63510309Pending
  • Intra-esophageal Or Intra-lesional Use Of Long-acting Fluticasone Propionate Injectable SuspensionApplication 63413167Pending
  • Process For Making Drug Crystals Of Desired Size Distribution And MorphologyApplication PCTUS2020027797Pending

Related companies, and why

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .